BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20230312T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20231105T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20250309T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20251102T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Helsinki:20240904T100000
DTEND;TZID=Europe/Helsinki:20240904T103000
DTSTAMP:20260411T201650
CREATED:20240822T150659Z
LAST-MODIFIED:20241024T183101Z
UID:10000797-1725444000-1725445800@staging.digitalinsights.supremeclients.com
SUMMARY:Achieving Good Manufacturing Production (GxP) compliance with NGS (EMEA)
DESCRIPTION:New guidelines for the viral safety evaluation of biotechnology products from the International Council for Harmonisation (ICH) recommend replacing multiple in vivo and in vitro assays with next-generation sequencing (NGS) to maintain good manufacturing practices. \nIf that sounds like a lot\, we’ve got you covered. In this webinar\, we’ll explore how you can easily apply NGS analysis to GxP with the QIAGEN CLC Genomics platform. Make compliance intrinsic to your workflow and ensure product quality\, data integrity and patient safety. \nYou’ll learn how to: \n\nAssess biosafety\, ensure integrity and perform quality control in the biotech industry with NGS\nImplement and maintain GxP with the QIAGEN CLC Genomics platform\nAdd your existing applications and extend their use through the CLC interface
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/achieving-good-manufacturing-production-gxp-compliance-with-ngs-emea/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/10/S_9299_QDI_CLC_Gi973088652_16x9_Large-1200px_49128-1140x641-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240904T130000
DTEND;TZID=America/Halifax:20240904T133000
DTSTAMP:20260411T201650
CREATED:20240822T151120Z
LAST-MODIFIED:20241024T183101Z
UID:10000798-1725454800-1725456600@staging.digitalinsights.supremeclients.com
SUMMARY:Achieving Good Manufacturing Production (GxP) compliance with NGS (Americas)
DESCRIPTION:New guidelines for the viral safety evaluation of biotechnology products from the International Council for Harmonisation (ICH) recommend replacing multiple in vivo and in vitro assays with next-generation sequencing (NGS) to maintain good manufacturing practices. \nIf that sounds like a lot\, we’ve got you covered. In this webinar\, we’ll explore how you can easily apply NGS analysis to GxP with the QIAGEN CLC Genomics platform. Make compliance intrinsic to your workflow and ensure product quality\, data integrity and patient safety. \nYou’ll learn how to: \n\nAssess biosafety\, ensure integrity and perform quality control in the biotech industry with NGS\nImplement and maintain GxP with the QIAGEN CLC Genomics platform\nAdd your existing applications and extend their use through the CLC interface
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/achieving-good-manufacturing-production-gxp-compliance-with-ngs-americas/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/10/S_9299_QDI_CLC_Gi973088652_16x9_Large-1200px_49128-1140x641-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240904T130000
DTEND;TZID=America/Halifax:20240904T150000
DTSTAMP:20260411T201650
CREATED:20240814T191059Z
LAST-MODIFIED:20241024T183058Z
UID:10000790-1725454800-1725462000@staging.digitalinsights.supremeclients.com
SUMMARY:QIAGEN IPA new user training
DESCRIPTION:Are you new to QIAGEN Ingenuity Pathway Analysis (IPA) or interested in expanding your skill set? Join us as we learn more on large dataset analysis and knowledge base queries using QIAGEN IPA. \nYou’ll learn to: \n\nUpload multiple dataset types (e.g.\, RNA-seq\, proteomics\, metabolomics) and perform interactive core/pathway analysis in IPA\nLearn how to interpret different results\, including pathways\, key regulators\, impact on biological functions/diseases and more\nCompare different experimental conditions (e.g.\, single-cell clusters\, disease types) and identify similarities and contrasts\nGenerate a network for hypothesis generation\, even without a dataset or experimental design\n\nAlready have an IPA license? Install IPA and start using it now. \nLearn more about IPA or request a free trial.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/qiagen-ipa-new-user-training/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9978_QDI_IPA_Gi609807396_16x9_Medium-720px_50570.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240905T130000
DTEND;TZID=America/Halifax:20240905T140000
DTSTAMP:20260411T201650
CREATED:20240814T190613Z
LAST-MODIFIED:20241024T183055Z
UID:10000789-1725541200-1725544800@staging.digitalinsights.supremeclients.com
SUMMARY:Custom patient cohorts: Making discoveries with curated genomics data
DESCRIPTION:Are you interested in exploring how you can evaluate phenotypic differences between custom cohorts? You can learn more about drug response\, survival\, co-expressing biomarkers\, mutations and more based on gene expression. \nIn this webinar\, you'll learn how to investigate patient cohorts using high-quality curated genomic repositories like the QIAGEN OmicSoft Lands database. You'll be able to to perform in-depth investigations across diverse data-sources\, including GEO datasets\, TCGA and more. \nIn this webinar\, attendees will learn how to \n\nEasily locate studies of interest using OmicSoft Lands APIs\nGenerate custom cohorts based on expression levels of biomarker(s) of interest\nThoroughly investigate drug response and patient survival for these custom cohorts\nStudy variants/mutations present in these patient population and their association with disease pathology
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/discoveries-from-custom-patient-cohorts-drug-response-survival-curves-mutations-and-more-using-high-quality-genomics-public-data-and-peer-reviewed-literature/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/08/S_1212_8_QDI_QDI_BKB_Original_62142.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Helsinki:20240907T080000
DTEND;TZID=Europe/Helsinki:20240911T170000
DTSTAMP:20260411T201650
CREATED:20240829T162719Z
LAST-MODIFIED:20241024T183102Z
UID:10000799-1725696000-1726074000@staging.digitalinsights.supremeclients.com
SUMMARY:QIAGEN presents poster at 2024 European Congress of Pathology
DESCRIPTION:QIAGEN will be at the 36th European Congress of Pathology (ECP) in Florence from September 7-11\, 2024\, in Florence\, Italy. \nAt the event\, be sure to check out our poster that we are presenting in collaboration with a leading pharmaceutical company showing how our clinical decision support software\, QCI Interpret\, provides rapid and accurate interpretation of gBRCA genes in a clinical lab setting. In the study\, 10 partner labs were asked to assess 48 retrospective analyses of BRCA variants and compare their variant classifications with the automated classifications computed by QCI Interpret. Results showed QCI Interpret was concordant with 93% of all cases. \n \nFeatured Poster: Spadolini Pavilion (Upper Floor) \nMolecular Pathology Session | September\, 10\, 2024\, 9:30–10:30 a.m. \nPoster number: 009. Title: “QIAGEN clinical decision support software provides rapid and accurate interpretation of gBRCA variants in a clinical lab setting”
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/qiagen-36th-european-congress-of-pathology-ecp/
LOCATION:Florence\, Italy
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/10/S_1418_4_QDI_QCI_Italy_Florence.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240910T130000
DTEND;TZID=America/Halifax:20240910T143000
DTSTAMP:20260411T201650
CREATED:20240814T190300Z
LAST-MODIFIED:20241024T183055Z
UID:10000788-1725973200-1725978600@staging.digitalinsights.supremeclients.com
SUMMARY:Metatranscriptome analysis\, annotation and pathways investigations using CLC Genomics Workbench
DESCRIPTION:Using CLC Genomics Workbench\, we will go through a pipeline for analyzing metatranscriptome NGS data from microbial communities and perform pathways interpretation on it. \n\nImport "raw" NGS sequencing data and prepare the samples for analysis\nFind relevant annotated genomes with a curated reference database while removing ribosomal RNA with the SILVA database (database of rRNAs)\nDe novo assemble the unclassified reads into contigs to also find transcripts of taxa not present in the reference database\nMap the reads to the assembled contigs and database · Build a functional profile of the samples to get an abundance of GO-terms.\nStatistical analysis of the groups\nPathway analysis on the differential abundance analysis using MetaCyc database.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/metatranscriptome-analysis-annotation-and-pathways-investigations-using-clc-genomics-workbench/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/10/0be0fc6f-c5b4-487a-8eb9-70ec50b6fad1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240912T110000
DTEND;TZID=UTC:20240912T120000
DTSTAMP:20260411T201650
CREATED:20240821T173902Z
LAST-MODIFIED:20241024T183100Z
UID:10000796-1726138800-1726142400@staging.digitalinsights.supremeclients.com
SUMMARY:Expanding neoantigen discovery with COSMIC
DESCRIPTION:Neoantigens are among the newest promising targets for cancer treatment. Unlike tumor-associated antigens\, neoantigens are produced only by tumor cells. These unique molecular markers are highly visible to the immune system\, making them ideal for personalized immunotherapies. They may also be able to predict both tumor survival prognosis and immune checkpoint blockade responses. Neoantigens are presented by human leukocyte antigen class I molecules (HLA-I) to T cells\, providing an ideal pathway for detection by shotgun proteomics. To identify these elusive targets\, scientists often rely on whole exome sequencing (WES)-derived data. However\, this approach can miss rare or low-frequency mutations\, especially in cancers with a low tumor mutational burden (TMB). \nThe Catalogue of Somatic Mutations in Cancer (COSMIC) can bridge this gap by providing researchers with detailed information about somatic mutations in human cancer. Unlock the full potential of neoantigen-targeted therapies and enhance traditional approaches like WES with our comprehensive\, expert-curated knowledge base. \nIn this webinar\, we’ll learn to: \n\nUncover and validate potential neoantigens with a recent peer-reviewed study that uses COSMIC mutation data from human hepatocellular carcinoma (HCC)\, a low-TMB cancer\nApply the benchmarking results of neoantigen detection performance using HCC-specific variants from COSMIC or DepMap\nTake full advantage of the breadth and accuracy of COSMIC data with downloaded content and other resources\n\nCOSMIC’s scientific and curation team will also answer your questions live during the webinar. \n  \nSpeaker: Kyle Nilson\, PhD \nKyle Nilson\, PhD\, is a sequencing-focused molecular biologist with a background in biochemistry and technical support. As a field software trainer at QIAGEN Digital Insights\, Dr. Nilson works closely with QIAGEN’s global bioinformatics team to provide direct customer support and assist with software training\, implementation\, and optimization. He earned his Ph.D. in molecular and cellular biology from the University of Iowa\, where he studied the regulation of RNA polymerase II transcription and co-transcriptional mRNA processing. Dr. Nilson then completed his postdoctoral training at Penn State and Cornell University\, focusing exclusively on next-generation sequencing method development to study chromatin.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/expanding-neoantigen-discovery-with-cosmic/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240917T130000
DTEND;TZID=America/Halifax:20240917T143000
DTSTAMP:20260411T201650
CREATED:20240814T185750Z
LAST-MODIFIED:20241024T183055Z
UID:10000787-1726578000-1726583400@staging.digitalinsights.supremeclients.com
SUMMARY:OmicSoft Diseaseland Training
DESCRIPTION:Per feedback of scientists interested in taking advantage of non-oncological diseases (inflammatory\, infectious\, metabolic and more) as well as normal tissues (example toxicology/target safety assessment) omics\, we are hosting this training focused OmicSoft Diseaseland. OmicSoft Diseaseland is a repository which contain high quality curated ‘omic data (RNA-seq\, scRNA-seq\, microarray and more) from diverse data-sources (example GEO\, SRA\, GTEx and many more). While this training will be focused on leveraging public data\, users can use this knowledge to navigate through their institution’s internal lands (omic data repositories) as well. \nAttendees will learn to perform queries similar to below \n\nHow is a gene (or a set of genes) expressed across different conditions? (Conditions = diseases\, tissues\, treatments\, cell types and more)\nHow is expression of a gene correlated with expression of other genes?\nFor a list of genes can we generate a heatmap studying their expression across different conditions?\nHow do you get a list of biomarkers specific to a condition from public studies?
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/omicsoft-diseaseland-training/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1188_7_QDI_QDI_OmicSoft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240926T110000
DTEND;TZID=UTC:20240926T123000
DTSTAMP:20260411T201650
CREATED:20240821T172900Z
LAST-MODIFIED:20241024T183100Z
UID:10000795-1727348400-1727353800@staging.digitalinsights.supremeclients.com
SUMMARY:Third Annual Clinical Hereditary Disease Diagnostics Summit "Exome experts: Improving the interpretation and integration of exome testing in routine clinical care"
DESCRIPTION:Industry leaders discuss how to improve the speed\, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases \nClinical exome testing is revolutionizing the diagnosis of rare and inherited diseases. Its ability to quickly pinpoint the genetic causes of complex conditions has made it a critical component of personalized medicine\, leading to earlier diagnoses\, targeted treatments and improved patient outcomes. However\, without the right strategies\, databases and informatics tools\, clinical exome testing remains inaccessible for many small to mid-sized laboratories. \nThe Third Annual Clinical Hereditary Disease Diagnostics Summit hosted by QIAGEN Digital Insights will examine the incredible opportunities—and challenges—of brining clinical exome testing in-house. Join industry leaders as they discuss how labs\, regardless of size\, budget and experience\, can integrate exome testing into routine clinical care with transformative impact for providers and their patients. \nFeatured topics will include: \n\nEmerging trends and recent technological advancements in genetic testing\nOvercoming challenges of interpreting complex genetic data from genome\, exome\, and next-generation sequencing panels\nHow to integrate genetic testing into clinical practice with consideration of efficiency\, cost\, and ethics\nFuture directions for the field and how to prepare your lab for innovation
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/exome-experts-improving-the-interpretation-and-integration-of-exome-testing-in-routine-clinical-care/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240926T130000
DTEND;TZID=America/Halifax:20240926T143000
DTSTAMP:20260411T201650
CREATED:20240814T192314Z
LAST-MODIFIED:20241024T183059Z
UID:10000794-1727355600-1727361000@staging.digitalinsights.supremeclients.com
SUMMARY:Investigating biomarkers with bulk and single-cell RNA-seq expression data
DESCRIPTION:QIAGEN Ingenuity Pathway Analysis (IPA) is designed to help you analyze and compare different types of 'omics data. In this webinar\, we’ll compare bulk RNA-seq and single-cell RNA-seq data to identify common regulators/targets and see how those regulators/targets associate with your phenotype of interest. We will also use sample-level public data to validate gene expression of common genes in tissues and/or cell type of interest. \nYou'll learn how to: \n\nGenerate a Comparison Analysis for bulk and single-cell RNA-seq\nIdentify significant common genes with the Compare feature\nBuild a custom network associating common genes to a phenotype\nExamine sample- and cell-level expression in OmicSoft content
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/compare-bulk-rnaseq-and-single-cell-rnaseq-expression-data-for-biomarkers-investigation/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9978_QDI_IPA_Gi609807396_16x9_Medium-720px_50570.jpg
END:VEVENT
END:VCALENDAR